Evaluation of Soy Isoflavones on Skin Ageing Parameters
NCT ID: NCT06047145
Last Updated: 2025-04-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
66 participants
INTERVENTIONAL
2023-10-27
2024-02-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Dietary Soy Protein on Facial Wrinkles in Postmenopausal Women
NCT04871750
Evaluation of the Anti-aging Efficacy of Two Dietary Supplements
NCT06032598
Efficacy and Safety of Skin Care Product in Aging Facial Skin
NCT04015063
Efficacy and Tolerance Evaluation of an Anti-age Food Supplement
NCT03274154
A Randomized, Double-blinded, Placebo Controlled, Monocentric Study to Evaluate the Anti-ageing and Skin Brightening Benefit of the Test Product in Healthy Female Subjects
NCT04276753
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
soy isoflavones
One oral capsule daily containing 200mg soy isoflavones for 84 days
soy isoflavones
1 capsule daily for 84 days
placebo
One oral capsule daily containing equivalent placebo for 84 days
Placebo
1 capsule daily for 84 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
soy isoflavones
1 capsule daily for 84 days
Placebo
1 capsule daily for 84 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Sex: female.
3. Age: from 40 to 65 years (inclusive).
4. Phototype: I to IV on the Fitzpatrick scale.
5. Post-menopausal subject, with last menstrual period at least 12 months prior to screening and who is not using hormonal contraception.
6. Subject having Crow's feet wrinkles from grade 2 to 5 on Bazin's scale.
7. Subject having under eyes wrinkles.
8. Subject agreeing not to change her alimentary and cosmetic habits during the study.
9. Subject, able to understand the study related information and to give a written informed consent.
10. Subject having given freely and expressly informed consent.
11. Subject able and willing to comply with protocol requirements.
12. Subject affiliated to a health social security system.
Exclusion Criteria
2. Subject deprived of her freedom by administrative or legal decision.
3. Subject under guardianship or unable to provide consent.
4. Subject in a social or healthcare institution.
5. Subject suspected to be non-compliant according to the investigator's judgment.
6. Subject participating in any other clinical study or being in an exclusion period for a previous study.
7. Subject having crow's feet wrinkles with grades \< 2 or \> 5 on Bazin's scale.
8. Subject with a tattoo, a scar, moles, too many hairs or anything on the studied zones which might interfere with the evaluation.
9. Personal or family history of breast, uterine or ovarian cancer as per investigator judgement.
10. Subject with personal history of cancer.
11. Subject with a condition or receiving a medication which, in the investigator's judgement, put the subject at undue risk.
12. Subject suffering from a severe or progressive disease, likely to interfere with the measured parameters.
13. Subject with any skin or systemic disease (acute and/or chronic), ongoing or in the previous year, likely to interfere with the measured parameters or to put the subject at undue risk.
14. Subject with known history of or suffering from autoimmune disease and/or immune deficiency.
15. Subject with allergies or intolerance to soy or soy products.
16. Subject having history of allergy or hypersensitivity to any of the components of the tested product.
17. Subject under anti-coagulant treatment.
18. Subject under thyroid hormones treatment.
19. Subject under osteoporosis treatment other than vitamin D and calcium.
20. Subject having started or stopped supplements used to treat menopausal symptoms, which may affect measured parameters, such as phytoestrogens, Black Cohosh, dehydroepiandrosterone (DHEA), hyaluronic acid, collagen, NADH, resveratrol soy supplements, etc. within one month prior to screening.
21. Subject having received injection with botulinum toxin on Crow's feet wrinkles in the year before the screening visit.
22. Subject having received injection with botulinum toxin on other zone of the face in the past 6 months before the screening visit.
23. Subject having received injection of filling product on the studied zones (crow's feet and under eye wrinkles, cheekbones and forearms) in the year before the screening visit.
24. Subject having received tensor threads on the face in the two years before the screening visit.
25. Subject having received injection of mesotherapy in the face in the past 3 months before the screening visit.
26. Subject having received professional peeling on the face and forearms in the past 3 months before the screening visit.
27. Subject having received a treatment with a laser on the face or forearms in the past 6 months before the screening visit.
28. Subject under oral hormonal substitutive treatment during the year previous the screening visit.
29. Subject receiving any long-term medical treatment or any treatment that, in the opinion of the clinical investigator, may interfere with test results or put the subject at undue risk.
30. Subject undergoing a topical treatment on the test area (forearms and face) or a systemic treatment:
* corticosteroids during the 2 previous weeks and during the study.
* retinoids and/or immunosuppressors during the 3 previous months and during the study.
31. Intensive exposure to sunlight within the previous month and foreseen during the study without adequate sun protection, as per the investigator's judgement.
32. Exposure to artificial UV or spray tan in the month preceding the screening or during the study.
33. Subject with an excessive consumption of alcohol (more than 2 glasses of wine per day) and/or tobacco (more than 10 cigarettes per day).
40 Years
65 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eurofins Dermscan Pharmascan
INDUSTRY
The Archer-Daniels-Midland Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eurofins Dermscan Pharmascan
Villeurbanne, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CTB2022TN110
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.